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ABSTRACT
Objective: Oncotype DX, a 21-gene assay, was clinically validated as a
predictor of 10-year recurrence-free survival and treatment response in
patients with early-stage estrogen-receptor-positive, lymph-node negative
breast cancer (ER+ LN- ESBC). This study determined “real-life” alter-
ation in treatment decision and economic implications of Oncotype DX
use in women with ER+ LN- ESBC.
Methods: Clalit Health Services (CHS, Tel Aviv, Israel), determined the
proportion of women in low, intermediate and high-risk groups in
the ﬁrst 368 Oncotype DX assays performed, the change of adjuvant
therapy recommendation following the recurrence (RS) results from
Oncotype DX use, and associated chemotherapy costs. The risk of
recurrence-free survival was derived from prespeciﬁed statistical
protocols of NCI-sponsored trials conducted by NSABP (B-14 and
B-20). Utilities were literature based. A 3% discount rate was
employed.
Results: Oncotype DX altered recommendations of 40% of patients, 84%
of whom were changed from hormone + chemotherapy to hormonal
therapy alone. Among high-risk women, 8% switched actual treatment
from hormonal therapy to hormone + chemotherapy. By reducing the
chemotherapy disutility, quality-adjusted life-years (QALY) increased
0.170 years. Use of Oncotype DX costs $10,770 per QALY gained. Sen-
sitivity analyses revealed that risk reduction in the low-risk population, the
cost of adverse events, and the relative risk reduction of recurrence were
the most inﬂuential variables.
Conclusion: Oncotype DX resulted in net QALY gain and increased
overall costs, with an incremental cost-effectiveness ratio of $10,770. For
CHS, Oncotype DX represents an effective and affordable approach to
favorably affect the lives of women with ESBC.
Keywords: Breast cancer, costs, early stage breast cancer, economics, gene
assay, molecular classiﬁer, Oncotype DX.
Introduction
Approximately 90 women per 100,000 are diagnosed yearly with
breast cancer in Israel [1]. Breast cancer remains among the most
common cancers in women, and the most common cause of
death among women between the ages of 40 and 79 [2]. Several
large randomized clinical trials demonstrated the beneﬁt of hor-
monal therapy in patients with estrogen receptor-positive (ER+)
early-stage breast cancer (ESBC). An important decision for a
patient with ER+, lymph node-negative (LN-) ESBC is whether to
also undergo adjuvant chemotherapy after primary surgery to
prevent or delay distant recurrence. Chemotherapy-related
adverse events occur in almost all patients, and more than 1 in 10
women experience a serious or life-threatening event [3].
Between 1 in 100 and 1 in 500 women die from side effects
related to the administration of chemotherapy. Other adverse
effects include ovarian failure, cardiotoxicity, nausea, and hair
loss. Consensus guidelines recommend considering adjuvant che-
motherapy if tumor size is greater than 0.6 cm [4]. Experts do
not recommend routine use of adjuvant chemotherapy for
patients over 70 years old and advocate for individualized treat-
ment with consideration of comorbid conditions [4].
Enhanced public health efforts to detect breast cancer, such as
mammographic screening, have increased detection at earlier
stages of disease [5]. The success of these efforts has resulted in
physicians and patients more regularly facing the question: Do
the beneﬁts of adjuvant chemotherapy outweigh the medical
risks and known adverse effects on quality of life? The difﬁculty
in answering this question is supported by recent evidence
showing wide variation in the propensity to prescribe adjuvant
chemotherapy, a variation that cannot be explained by charac-
teristic risk factors such as age, tumor size, and histology [3,6].
Thus, an active area of oncology research is identifying addi-
tional reliable predictors of recurrence in ESBC that would assign
risk more accurately and help guide the decision to prescribe
adjuvant chemotherapy.
Oncotype DX (Genomic Health, Inc., Redwood City, CA,
USA) is a genomic test that predicts the average rate of distant
recurrence of breast cancer and response to adjuvant chemo-
therapy treatment. The Oncotype DX assay uses a reverse-
transcriptase, polymerase chain reaction process to quantify the
presence of speciﬁc mRNA for 16 cancer genes, and 5 reference
genes in parafﬁn samples obtained from a breast cancer biopsy.
The results are combined into a single score, quantiﬁed on a scale
of 0 (lower risk) to 100 (higher risk). The test has the most value
as a continuous variable; however, patients can be further sub-
divided into three risk groups: patients receiving a score of 0–17
are considered to have a low risk of recurrence, while patients
with a score of 18–30 are considered to have an intermediate risk
of recurrence. Patients with a score of 31 or higher are considered
to have a high risk of recurrence.
Oncotype DX’s clinical validity was tested in prespeciﬁed
subgroup analyses of randomized clinical trials (National Surgi-
cal Adjuvant Breast and Bowel Project studies [NSABP] B-14
and B-20), and was shown to independently predict distant
recurrence of breast cancer at 10 years and response to
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adjuvant chemotherapy using cyclophosphamide-methotrexate-
5-ﬂuorouracil regimens [7,8].
Experience from several university- and community-based
groups has shown that the Oncotype DX assay has inﬂuenced
decisions about whether to undergo chemotherapy [9–12]. In
studies conducted in the United States and Israel, 20% to 25% of
women classiﬁed as low risk of distant recurrence elected to
change therapy from adjuvant chemotherapy plus hormone
therapy to hormone therapy only [10,13–15]. For the 25 out of
100 women predicted to have a high risk of distant recurrence,
the Oncotype DX assay identiﬁed at least 1 woman per 100 who
initially decided to use only hormone therapy and subsequently
elected to also undergo a course of adjuvant chemotherapy based
on the high Oncotype DX score [8].
In February 2006, Clalit Health Services (CHS), Israel’s
largest health-care organization with 3.6 million members, was
the ﬁrst public health insurer to reimburse the assay outside the
United States. The coverage decision was based on the assay’s
clinical validation, recommendations by Israeli oncology opinion
leaders, and ﬁndings of potential cost-effectiveness of the assay
under a wide range of assumptions [15,16].
The primary aim of this study was to assess the validity of the
cost-effectiveness of Oncotype DX compared with traditional
prognostic pathways in the diagnosis and treatment of ER+, LN-,
ESBC from an Israeli health-care provider perspective. A second-
ary aim was to assess the factors that inﬂuence the cost-
effectiveness of Oncotype DX use.
Methods
Analytical Framework
The analytical framework was a Markov model, which simulated
the costs associated with and without use of the Oncotype DX
assay (Fig. 1). The cost implications of both patient
groups—patients using Oncotype DX and those without—were
compiled. The analysis was performed from a payer’s perspec-
tive. CHS provided the data on the risk of recurrence in the
Israeli population. Sensitivity analyses were performed to assess
the impact of different variables on the cost-effectiveness of the
assay.
Data Sources
Data was collected from the ﬁrst 368 Oncotype DX assays reim-
bursed by CHS. Researchers collected forms completed by the
treating oncologist containing information on relevant biological
data, the physician’s treatment recommendation before knowl-
edge of Oncotype DX assay results, and the treatment to be
offered to the patient according to each of the three possible risk
levels: low, intermediate, and high. Data on the actual treatment
provided to the patient was collected from CHS’s electronic
billing database.
Risk of Recurrence and Death
The annual risk of death by age for women was based on data
from the National Center for Health Statistics [17]. Along with
data from NSABP studies B-14 and B-20 published in 2004 and
2006 by Paik et al., these data were used to estimate the risk of
distant recurrence [7,8].
Costs
The cost of the assay was based on the manufacturer’s suggested
retail price of $3460. The CHS provided costs for chemotherapy
and supportive costs equal to $3540 and $243, respectively
(Table 1). The incidence of early adverse events was based on
published reports of key trials of anthracycline therapy [6]. Late
adverse events include ovarian failure and cognitive dysfunction.
Management of chemotherapy-related adverse events cost
$2249, and the associated cost per subsequent breast cancer
recurrence was approximately $10,000. Cycle length for time
until recurrence or death was 1 year, and a time discount rate of
3% was applied for both costs and beneﬁts as per the recom-
mendations made by the US Panel on Cost-Effectiveness in
Health and Medicine [18].
Figure 1 Markov diagram. Level of risk according
to Oncotype DX. Values without quotations are
known to physician/patient, whereas values with
quotations are unknown to physician/patient. Adj
CT, adjuvant chemotherapy.
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Health Utilities
Health utility scores, which are quantitative representations
(0 = death, 1 = perfect health) of the desirability of a particular
health outcome, were used to calculate quality-adjusted life-years
(QALY). Utility scores for the following health states were
obtained from the literature: breast cancer during chemotherapy,
breast cancer recurrence, and second primary cancer caused by
chemotherapy. Utility scores were derived from the sum of the
disutility associated with chemotherapy and the disutility associ-
ated with recurrence (Table 1) [19–23].
Sensitivity Analyses
In the one-way sensitivity analysis, each of the parameters that
drive the model were varied one at a time. These model param-
eters can be viewed in Figure 2. The impact of the parameter on
major performance metric, cost per QALY, was noted. Param-
eters were then sorted by decreasing level of importance and
plotted with order of importance on the vertical axis and change
in cost per QALY on the horizontal axis.
Probabilistic sensitivity analysis (PSA) employs a Monte
Carlo simulation to assess the variability of the cost per QALY as
key parameters independently change according to pre-assigned
probability distributions. These distributions capture the range
of variability likely for each parameter. In the PSA, each key
parameter is modeled according to distributions for the type of
parameter typically reported in Value in Health publications.
Beta distributions were used for proportions. Normal distribu-
tions were used for logarithm of costs and relative risk reduc-
tions. Normal distributions were used for QALY losses
associated with chemotherapy and recurrence of breast cancer.
Ranges were based on literature values for that variable if
reported (i.e., recurrence rates); otherwise, they were based on
norms of ranges published for PSAs in Value in Health over the
past 2 years (Fig. 2).
Quality of Evidence
Evidence was sought from the best available sources, including
the clinical trial itself, based on systematic searches of the litera-
Table 1 Relative reduction of recurrence by Oncotype DX risk group, cost and utilities
Parameter
Mean input
values Low High Distribution Data source
Evidence
grade
Relative reduction of recurrence with chemotherapy,
by Oncotype DX risk group
Low-risk 131% 46% 373% Lognormal Paik [8] I-A
Intermediate-risk 61% 24% 155% Lognormal Paik [8] I-A
High-risk 26% 13% 52% Lognormal Paik [8] I-A
Costs, average per patient
Associated with chemotherapy
Adjuvant chemotherapy regimen $3,540 $3,003 $4,173 Lognormal CHS P-A
Supportive care $243 $47 $1,259 Lognormal CHS P-A
Adverse events $2,249 $434 $11,650 Lognormal CHS P-A
Per recurrence $10,000 $1,930 $51,803 Lognormal CHS P-C
Oncotype DX $3,460 — — Not applicable CHS P-A
QALY loss with chemotherapy and cancers
Chemotherapy 0.5 0.3 0.7 Normal [19,21–23] P-C
Recurrence 9.1 6.5 12.6 Normal [19,21–23] P-C
Other assumptions
Discount rate (for NPV computations of recurrence costs) 3% — — Not applicable Lipscomb [18] P-A
Time horizon, years 30 or lifetime — — Not applicable Expert opinion P-A
See Appendix for summary of evidence grade.
CHS, Clalit Health Services; NPV, net present value; QALY, quality-adjusted life-years.
Figure 2 Sensitivity analysis tornado diagram. *At lowest range of input variable, Oncotype DX beneﬁts patients and saves costs. QALY, quality-adjusted life-years.
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ture using PubMed (United States National Library of Medicine,
Bethesda, MD) and ISI Web of Knowledge Web of Science
(Thomson Reuters, New York, NY, USA). In instances where no
published data was available, evidence was based on consulta-
tions with experts. The quality of the evidence is graded based on
study design, results, and limitations using two grading systems
[24,25]. The ﬁrst system assesses evidence pertaining to inference
about treatment effects. The grading system assumes that ﬁnd-
ings from a well-controlled randomized clinical trial represent
level A evidence, whereas ﬁndings from an observational study
represent level B evidence. Level C evidence derives from other
sources, such as expert opinion or small case series. The grading
level is altered by one or two levels based additional criteria, such
as strength of association, consistency of ﬁndings, level of poten-
tial reporting bias, concerns about study limitations, and gener-
alizability of the ﬁndings.
For the second grading system, level A evidence represents
data obtained from the stakeholder. For example, if the analysis
is done from the perspective of the Centers for Medicare and
Medicaid services (CMS), level A evidence would be based on
CMS claims analyses. Another example is obtaining evidence
from a utility assessment project, where the participants are a
random sample from the stakeholder’s stated constituency. Level
B evidence involves obtaining estimates that pertain to the stake-
holder perspective, but was not directly analyzed for this project
(e.g., from a review of the literature). Level C evidence represents
data obtained from other database sources, such as utility or cost
registries. Level D evidence represents data from other sources,
such as Delphi panel of experts. The grading level can be altered
to reﬂect strengths and limitations of the study. It is worth noting
that utility or cost data from a randomized controlled trial may
be graded from A to C, depending on the particular relevance of
the information to the stakeholder. For example, cost data ana-
lyzed in a trial in which most of the participants were from a
country or health-care system substantially different from that of
the stakeholder has lower relevance, and so may be assigned to
level C evidence.
Results
Records were assessed for the ﬁrst 368 Oncotype DX assays
ordered at CHS; however, the ﬁrst 55 patients did not have a
reported treatment recommendation prior to ordering the test.
This is typical with introduction of a new technology because 1)
the clinicians are learning about the technology and how to
interpret the results, and 2) CHS physicians decided subsequent
to ﬁrst using the test to obtain prospective information about
their decision-making processes. The median patient age was
57 years (range 29–81 years) (Table 2). The median tumor size
was 1.5 cm (range 0.3–4.5 cm). Using criteria from the American
Joint Commission on Cancer [26], 9% of patients had tumor
grade 1, 66% had tumor grade 2, and 25% had tumor grade 3.
The proportion of patients classiﬁed by the Oncotype DX assay
as low-risk (score 0–17), intermediate-risk (score 18–30), and
high-risk (score > 30) was 40, 45, and 16%, respectively.
Prior to receiving the assay results, chemotherapy was offered
to 174 patients (56%) (Table 3). After receiving the assay results,
125 patients’ (40%) actual treatment differed from the initial
recommendation. One hundred ﬁve patients (34%) received only
hormone therapy instead of the initial recommendation of adju-
vant chemotherapy plus hormone therapy.
The most substantial change from the original physician rec-
ommendation occurred among patients classiﬁed as low-risk by
Oncotype DX. Prior to Oncotype DX classiﬁcation, 63 low-risk
patients (50%) were recommended to undergo chemotherapy;
none of these patients subsequently received chemotherapy
(Table 3). Among patients with intermediate-risk Oncotype DX
score, the proportion of patients undergoing chemotherapy
declined to 33% from an initial 51% of patients recommended to
receive chemotherapy. Among high-risk patients, the proportion
of patients undergoing chemotherapy increased from 85% to
93% of patients recommended to undergo chemotherapy prior
to receiving information on the Oncotype DX score.
Oncotype DX costs $3460 per patient (Table 4). A cost
savings resulted from the reduced use of adjuvant chemotherapy.
This is because a lower percentage of patients actually received
adjuvant chemotherapy than were initially recommended by a
physician prior to receiving information regarding their risk clas-
siﬁcation from Oncotype DX. Savings associated with chemo-
therapy, supportive care, and fewer adverse events were $968,
$66, and $615, respectively. The proper administration of che-
motherapy to high-risk patients, who switch from hormone-only
treatment after Oncotype DX, resulted in $66 dollars of savings
from preventing recurrence. The net average cost associated with
Oncotype DX testing was $1828 per patient. For CHS, Oncotype
Table 2 Summary of the baseline patient and tumor characteristics
Characteristic Value (range)
Demographics
Female, % 99
Age, mean (range), years 57 (29–81)
Tumor staging
Median tumor size, cm 1.5 (0.3–4.5)
Tumor grade,* %
1 9
2 66
3 25
Oncotype DX risk group (score)
Low-risk ( 0–17), % 40
Intermediate-risk (18–30), % 45
High-risk (> 30), % 16
*American Joint Commission on Cancer criterion.
Table 3 Adjuvant chemotherapy recommended before compared with actual use after receiving information on Oncotype DX risk status
Oncotype DX risk group
Proportion of patients by risk group
Total
Recommended chemotherapy
prior to Oncotype DX*
Recommended chemotherapy
after Oncotype DX†
Low risk (score 0–17) 63 (50%) 0 (0%) 127
Intermediate-risk (score 18–30) 72 (51%) 46 (33%) 140
High-risk (score > 30) 39 (85%) 43 (93%) 46
Total 174 (56%) 89 (28%) 313‡
*Percent in parentheses represents the proportion of patients in that risk group who were recommended to undergo chemotherapy prior to receiving information on Oncotype DX score.
†Percent in parentheses represents the proportion of patients in that risk group who actually underwent chemotherapy after receiving information on Oncotype DX score.
‡A total of 313 patients recorded treatment recommendations both prior to and after receiving the Oncotype DX assay.
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DX increased total costs by $1,560,520 in the ﬁrst year after
initial diagnosis of breast cancer and genomic testing ($0.0338
per member per month). Oncotype DX was projected to cost
$14,717 through risk reduction for the 8% of high-risk patients
who appropriately receive adjuvant chemotherapy as a result of
testing.
The average QALY gained per patient associated with
reduced use of adjuvant chemotherapy was 0.136 years
(Table 4). For the 8% of high-risk patients who initially were
recommended hormone therapy only and then switched to also
receive adjuvant chemotherapy, the average QALY associated
with reduction in recurrence was 0.034 years. The net QALY
gained was 0.170 years per patient. The resulting cost per QALY
gained was $10,770.
Figure 2 shows the results of the one-way sensitivity analyses.
The cost per QALY gained was less than $20,000 for all vari-
ables. The three most inﬂuential variables inﬂuencing the cost-
effectiveness of Oncotype DX were relative risk reduction in the
low risk population, the cost of adverse events, and the relative
risk reduction of recurrence in the intermediate risk population.
There is a 5% probability that the cost per QALY gained exceeds
$35,000 (Fig. 3).
Discussion
Adjuvant chemotherapy is a widely prescribed treatment in ER+,
LN- ESBC. Because the likelihood of distant recurrence within
10 years among all tamoxifen-treated patients is less than 20%,
professional commentators have claimed that at least 80% of
patients would be overtreated with adjuvant chemotherapy if it
were offered to everyone [8]. Prior to testing with Oncotype DX,
more than 50% of patients at CHS were recommended to
undergo adjuvant chemotherapy.
Oncotype DXwas developed, in part, to more reliably predict
who would beneﬁt from adjuvant chemotherapy, which then
should reduce the unnecessary use of adjuvant chemotherapy
among low-risk patients and increase the use of adjuvant che-
motherapy among high-risk patients. Oncotype DX has under-
gone rigorous clinical validation using prespeciﬁed statistical
protocols applied to randomized controlled trials [7,8], and has
been endorsed by guidelines of the American Society of Clinical
Oncology and the National Comprehensive Cancer Network as
a means to reduce risk and costs for cancer patients [4,27].
We project that patients’ lives will be extended and improved
by the avoidance of adjuvant chemotherapy among low-risk
patients and the use of adjuvant chemotherapy among high-risk
patients. With the CHS, use of Oncotype DX increases overall
costs by approximately $1828 per patient tested. Nevertheless, as
a consequence of improved quality-adjusted survival, the assay
costs no more on average than $11,000 per QALY gained. Exten-
sive sensitivity analyses showed that incremental cost-
effectiveness is likely to remain less than $12,000 under the most
reasonable assumptions, a value that is substantially below
thresholds of acceptable cost-effectiveness among countries in the
Organisation for Economic Co-operation and Development,
such as Israel [28].
This study has several limitations. First, the clinical data on
which the analyses were based came from a nonrandomly
selected sample of patients at CHS. It is possible that these
patients could potentially yield a higher proportion of patients’
decisions altered by Oncotype DX than the population at large.
For example, physicians may have selected patients in whom the
physician has substantial uncertainty about the optimal treat-
Table 4 Results
End point Mean value
Costs, per patient tested
Oncotype DX $3460
Reduced use of adjuvant chemotherapy (actual*)
Chemotherapy drugs ($968)
Supportive care ($66)
Adverse events ($615)
Recurrence costs (projected) $17
Total $1828
Total costs per plan*
First year after diagnosis and testing $1,560,520
After ﬁrst year from reduced recurrence risk ($52,422)
QALYs gained
Chemotherapy related 0.136
Recurrence 0.034
Total 0.170
Cost per QALY gained $10,770
*Reduction in chemotherapy costs were actually realized by Clalit Health Services. The
reduction in cost from reduced risk of recurrence—for the 8% of high-risk patients who
initially were recommended hormonal therapy only and then switched to also receive
adjuvant chemotherapy—are projections.
QALY, quality-adjusted life-years.
Figure 3 Acceptability curve and scatterplot.QALY, quality-adjusted life-years.
Economics of Genomic Risk Assay for Breast Cancer in Israel 385
ment recommendation. Second, the utilities applied in the model
were derived from the English-speaking literature and may not
fully characterize the preferences of patients in Israel. Third, the
validation of the assay was based on clinical trials conducted in
the United States [7,8]. Studies are underway in other countries,
such as Japan, to assess whether the ﬁndings of the pivotal trials
are maintained in other settings [29]. Fourth, we omitted some
potential long-term implications of breast cancer and its treat-
ments, such as the risk of local recurrence and risk of second
primary tumors associated with chemotherapy, as a result of
limited data [15,16,30]. Fifth, we examined the effect of the test
from the payer’s perspective. As such, we have not included
savings associated with lower indirect costs accruing to patients,
such as reduced work absenteeism associated with the chemo-
therapy regimen and management of its adverse events.
Conclusions
The CHS found that testing 368 patients with ER+, LN-, ESBC
with Oncotype DX increased their health-care costs by
$1,500,000. These higher overall costs associated with testing in
Israel, relative to cost-savings that have been estimated for the
United States, is likely consequence of the higher expenditures
per patient in the Israel for adjuvant chemotherapy and its
administration. The beneﬁts realized by patients were associated
with the avoidance of a loss in quality of life related to the lower
incidence of early adverse events (e.g., nausea/vomiting, hair loss,
and infections) from the reduced use of adjuvant chemotherapy.
Patients at low risk of recurrence who decided to forego adjuvant
chemotherapy can be reasonably expected to worry less about
the risk of late adverse events, such as cognitive dysfunction,
infertility, and second primary tumors. Among patients at high
risk of recurrence who switched to receiving adjuvant chemo-
therapy, they were projected to beneﬁt from a 25% to 30% lower
risk of recurrence and associated mortality from breast cancer.
Overall, Oncotype DX was projected to cost on average no more
than $11,000 per QALY gained, a value that is less than one-half
of generally accepted cost-effectiveness thresholds in developed
countries such as Israel [28].
Source of ﬁnancial support: Teva Pharmaceutical Industries Ltd., Kiryat
Nordau, Netanya, Israel.
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